Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma

Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma

Abstract Double-hit lymphoma (DHL) is among the most aggressive and chemoresistant lymphoma subtypes. DHLs carry genomic abnormalities in MYC, BCL2, and/or BCL6 oncogenes. Due to the simultaneous overexpression of these driver oncogenes, DHLs are highly resistant to frontline therapies. Most DHLs ov...

Full description

Bibliographic Details
Main Authors: Yuanhui Liu, Nancy G. Azizian, Yaling Dou, Lan V. Pham, Yulin Li
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Journal of Hematology & Oncology
Subjects:
Double-hit lymphoma
MYC
BCL2
XPO1
Targeted therapy
Combination therapy
Online Access:http://link.springer.com/article/10.1186/s13045-019-0803-9

Similar Items

Similar Items